<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

Anne Staylor

Former Senior Editor, Medtech Insight. +25 years in various leadership roles in business intelligence, marketing, communications, product management, and consulting for medical device industry, hospitals, physician groups, insurers. Registered nurse and former Director of Marketing for a national ambulatory surgery company.

Recent Posts

2 min read

A Bumpy Ride: Q122 Spinal Cord Stimulation Market Recap

By Anne Staylor on 6/30/22 9:30 AM

Q122 SCS Market revenues were up in the low-single digit YoY, but pandemic-related issues made it a bumpy ride

For Q122, the spinal cord stimulation (SCS) market was up in the low-single digits YoY in both the US and WW, but pandemic-related issues made it a bumpy ride. The market was down from pre-pandemic levels for most competitors, still weakened by pandemic disruption, staffing issues and a limping recovery. 
 

Among the many topics covered in detail in our comprehensive Q122 Spinal Cord Stimulation Market Recap* are:

Continue Reading
3 min read

Opportunities in Neuromodulation: Abbott at INS 2022

By Anne Staylor on 6/20/22 10:11 AM

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with SmartTRAK at INS 2022

Continue Reading
4 min read

INS 2022 Interview with Dr. Marc Russo: Dorsal Horn Dendrite Stimulation for SCS

By Anne Staylor on 6/7/22 9:30 AM

Dr. Marc Russo discusses dorsal horn dendrite stimulation, a new paradigm for SCS, and making it available to all manufacturers in an interview with SmartTRAK at INS 2022

Dr. Marc Russo, president of the International Neuromodulation Society (INS), presented exciting new research on dorsal horn dendrite stimulation (DHDS), a new paradigm for spinal cord stimulation (SCS), at the INS 15th World Congress, held May 21 to 26, 2022 in Barcelona, Spain. In an interview with SmartTRAK, Dr. Russo discusses the proposed mechanism of action for DHDS compared to traditional dorsal column stimulation, six-month study results in 27 patients and what’s next in terms of his research. 

And, in an unprecedented move, Dr. Russo decided not to patent DHDS and said he is giving the novel waveform as a “gift” to physicians, industry and patients, noting that it is deployable on all current SCS devices within the product range. To find out more about DHDS, including its characteristics and Dr. Russo’s vision for a more advanced version that could theoretically even “cure pain,” click on the video below of the interview conducted shortly after his presentation outside the Barcelona International Convention Centre (12:02 min). A link to download the  complete transcript of the interview is also provided below.

Continue Reading
10 min read

What’s New in Neuromodulation for Spring 2022

By Anne Staylor on 5/23/22 11:52 AM

In the market for neuromodulation, companies are developing spinal cord stimulation (SCS), deep brain stimulation (DBS) and other stimulation devices designed to treat a vast range of indications. Current and emerging devices are addressing care gaps in the treatment of chronic pain and movement disorders as well as epilepsy, Tourette syndrome, depression, pelvic floor dysfunction, peripheral artery disease, paralysis and spinal cord injuries.

Companies competing in the market for neuromodulation include Abbott*, Boston Scientific*, Medtronic*, Nevro*, Saluda Medical*, Newronika* and Axonics, just to name a few. To keep you up to speed on what’s new in neuromodulation, SmartTRAK highlights market updates covering clinical developments, patents, new research and other top news from Spring 2022.

SmartTRAK's Anne Staylor, Executive Editor, VP &GM of Neurotherapies, is in Barcelona attending the INS 15th Congress.

The following is just a small sampling of recent neuromodulation updates from around the world compiled, reviewed and posted daily by our SmartTRAK analysts.

Clinical Developments

  • Medtronic*
    • Medtronic announced the first patient implanted in its “Evaluation of Long-term Patient Experience with a Medtronic Closed-Loop SCS System” study of its investigative, closed-loop, ECAP-responsive device to treat back and limb pain. The prospective study is enrolling 90 patients across 10 centers in Australia.
    • A University of Florida-sponsored eight patient clinical trial will evaluate DBS to treat Tourette syndrome targeting two brain regions in each hemisphere of each patient and using two leads in each hemisphere connected to two Percept PC devices. Estimated study completion is Aug 2026. clinicaltrials.gov

  •  Boston Scientific*
    • Boston Scientific received FDA approval of its latest image-guided programming software, Vercise Neural Navigator with STIMVIEW XT. Developed in collaboration with Brainlab*, STIMVIEW XT provides real-time visualization of lead position and simulation modeling for Parkinson’s Disease and essential tremor treatment.
Continue Reading
1 min read

Wallaby Acquires phenox GmBH

By Anne Staylor on 4/21/22 6:41 PM

Wallaby Medical announced it has acquired phenox GmbH, including phenox's femtos GmbH, a German-based neurovascular company, for a total of ~$545MM (EUR 500MM) including milestone payments. SmartTRAK previously reported the possibility of the acquisition deal in early March 2022. Wallaby Medical acquiring phenox GmbH is one of the largest recent cross-border transactions in the medical device industry and will enable the Company to provide a wide range of neurovascular solutions to pts in the US, China, Europe, Japan and other international markets.

For more information about phenox, click to read "phenox Takes Aim at US Market with Novel Stroke Devices", SmartTRAK's interview with James Lago, President and CEO of phenox Inc., in which he discusses the Company's novel mechanical thrombectomy device and flow diverter, and what’s next in terms of bringing these technologies to the US market.

Continue Reading
3 min read

Abbott: Expanding the Ecosystem in DBS - An Interview with Binith Cheeran

By Anne Staylor on 4/13/22 9:50 AM

Abbott’s Binith Cheeran, MD, PhD discusses the latest trends in DBS as well as the Company’s strategies for growth in an interview with SmartTRAK

Binith Cheeran, MD, PhD, Abbott’s senior director of medical and clinical affairs for deep brain stimulation (DBS), discusses the latest trends, research and innovation in DBS in an interview with SmartTRAK. Abbott is focused on growing the market through patient education, improving access to care through its NeuroSphere Virtual Clinic and expanding the ecosystem in DBS through the Company’s connected devices.

To find out more, including Dr. Cheeran’s thoughts on primary cell vs rechargeable devices, use of specific image guidance systems, closed-loop DBS and empowering patients through digital health solutions, click on the video below to listen to the interview recorded online via Zoom (32:45 min). A link to download the transcript of the interview is also provided below.

Continue Reading
2 min read

Losing Steam Due to COVID: Q421/FY21 Spinal Cord Stimulation Market Recap

By Anne Staylor on 3/18/22 9:30 AM

Spinal Cord Stimulation companies had a strong start in Q421 but the market lost steam as the Omicron variant surged

Despite a strong start for all SCS competitors in Q421, the SCS market started to run out of steam late in the quarter as the contagious Omicron variant surged around the world, slowing elective procedures and resulting in a YoY low-single-digit decrease in SCS revenue in both the US and WW.  For the full year (FY), US and WW SCS revenues were up in the low-double-digits driven by strong YoY results in Q121 and Q221 in which COVID trends improved against easy comps in Q120 and Q220. 

Among the many topics covered in detail in our comprehensive Q421/FY21 Spinal Cord Stimulation Market Recap* are:

Continue Reading
3 min read

NANS 2022: What's New for Abbott Neuromodulation

By Anne Staylor on 2/28/22 11:11 AM

Abbott’s Allen Burton, MD discusses the Company’s new MRI labeling, expanded payer coverage for DRG, big data and digital initiatives in an interview with SmartTRAK at NANS 2022

Allen Burton, MD, Abbott Divisional Vice President, Medical Director Neuromodulation, discusses Abbott’s latest research and innovation in an interview with SmartTRAK at the North American Neuromodulation Society (NANS) Annual Meeting held January 13-14, 2022.

To find out more, including about the Company’s new MRI labeling, UnitedHealthCare coverage for DRG, big data and the status of Abbott’s digital initiatives, click on the video below to listen to the interview recorded live at NANS 2022. (30:18 min.) A link to download a complete transcript of the interview is also provided below.

Continue Reading
4 min read

Medtronic: The Future of Neuromodulation in 2022 and Beyond

By Anne Staylor on 2/22/22 9:30 AM

Medtronic Neuromodulation executives Dave Anderson and Charlie Covert discuss the Company and the future of neuromodulation in an interview with SmartTRAK at NANS 2022

Dave Anderson, Medtronic’s President Neuromodulation, and Charlie Covert, Vice President and General Manager of Pain Therapies, discuss the Company, pandemic and the future of neuromodulation in a wide-ranging interview with SmartTRAK at the North American Neuromodulation Society (NANS) 25th Annual Meeting held January 12-15, 2022 in Orlando, Florida.

To find out more about the Company’s newest innovations, expanding indications*, clinical research and strategies for driving growth in spinal cord stimulation (SCS) and deep brain stimulation (DBS), click on the following video recorded live at NANS 2022. (33:45 minutes.) Specific interview topics by time code are also outlined below. To download a complete transcript of the interview, click here.

Continue Reading
3 min read

An Interview with Nevro's D. Keith Grossman

By Anne Staylor on 2/16/22 10:00 AM

D. Keith Grossman, chairman, CEO and president of Nevro Corporation, discusses the Company, expanding indications and driving growth through innovation and evidence in an interview with SmartTRAK

Nevro’s Keith Grossman expects randomized controlled trials and recent FDA approvals for expanded indications--painful diabetic neuropathy (PDN) and non-surgical refractory back pain (NSRBP)--to provide a competitive edge and help drive growth in the market for spinal cord stimulation (SCS). To find out more, including Grossman’s take on Medtronic’s recent FDA approval for the diabetic peripheral neuropathy (DPN) indication, click on the following video recorded live* via Google Meet (40:20 min). Specific interview topics by time code are also outlined below. If you would like to download a complete transcript of the interview, please click here.

Continue Reading

    Follow Us on Social Media

    Recent Articles